Patients are travelling from across the North West, and from further afield, to reach Clatterbridge Private Clinic, where lung cancer ...
As our economy, society and daily life become increasingly dependent on data, new college graduates entering the workforce need to have the skills to analyze data effectively and from multiple angles.
Iza-bren (EGFR/HER3 ADC) plus serplulimab in SCLC extends momentum from FDA breakthrough designation in post-TKI/post-platinum EGFR-mutant NSCLC, broadening cross-histology interest. Final OS from ...
Given the importance of pathologic examination in patients with resectable NSCLC, we do not consider ORR per RECIST to be a clinically relevant end point when pathologic stage and response are ...
Good afternoon, and welcome to the Personalis Third Quarter 2025 Earnings Conference. [Operator Instructions] Please note that this event is being recorded. I will now hand you over to Caroline Corner ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer ...
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate ...
The data update from the Phase 3 NeoADAURA study was jointly presented by Personalis and AstraZeneca on September 7. The study evaluated osimertinib (TAGRISSO) as a neoadjuvant therapy in patients ...
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results